[2026 Latest] Pipeline of Anti-fibrotic Drugs (Disease-Modifying Therapies) and the Future of Cross-Disease Approaches

Introduction: The Paradigm Shift to Disease-Modifying Therapies (DMTs)

For many years, treatments for fibrotic diseases have primarily focused on symptomatic relief. However, with recent advances in therapeutic modalities and a clearer understanding of pathological mechanisms, the development of "anti-fibrotic drugs" as Disease-Modifying Therapies (DMTs)—aimed at delaying progression or even reversing fibrosis—is blossoming.

This article delves into the latest Phase 2 and Phase 3 pipelines, prioritizing the massive markets and high unmet needs of IPF (Idiopathic Pulmonary Fibrosis) and MASH (Metabolic Dysfunction-Associated Steatohepatitis). Additionally, we will explore the potential for expanding these indications to other organs, such as kidneys (CKD) and skin/systemic manifestations (SSc), utilizing a "Pan-fibrosis" approach.

Latest Pipeline: Anti-fibrotic Market Driven by IPF and MASH

The development race for anti-fibrotic drugs is largely driven by two mega-indications: IPF and MASH.

MASH: Dual Approach Targeting Metabolism and Fibrosis

The therapeutic development for MASH predominantly targets normalizing metabolism while actively reversing fibrosis. For more details, refer to our MASH Drug Development Landscape.

• THR-β Agonists (e.g., Resmetirom): Following FDA approval in 2024, these have become the first-line DMTs for improving liver-specific lipid metabolism and indirectly reversing fibrosis.
• FGF21 Analogues: These powerfully alleviate metabolic stress in hepatocytes, showing high promise for direct anti-fibrotic effects, with multiple pipelines advancing to Phase 3.
• GLP-1 Receptor Agonists and Combinations: Based on robust weight loss, the emerging trend involves combination therapies with existing DMTs (like THR-β agonists) to achieve synergistic anti-fibrotic efficacy.

IPF: The Rise of Novel Mechanisms

The IPF sector has entered a new phase of development, buoyed by the first novel drug approval in over a decade. See our IPF Drug Development Landscape for more info.

• PDE4 Inhibitors (e.g., Nerandomilast): Approved in 2025, this drug represents a new DMT addressing both inflammation and fibrosis, drawing significant market expectations.
• LPA1 Receptor Antagonists (e.g., BMS-986278 / Admilparant): Featuring a profile that potently inhibits fibroblast activation and migration, currently in ongoing Phase 3 trials.
• Shift to Inhaled Therapies: Delivering DMTs directly to the lungs while minimizing systemic side effects is gaining traction, evident in the formulation of inhaled agents like Tyvaso.

High-Potential Areas for Indication Expansion: CKD and SSc

A growing strategy among pharmaceutical companies is to leverage the Proof of Concept (PoC) gained in IPF or MASH to expand into other fibrotic diseases.

1. CKD (Chronic Kidney Disease): Renal fibrosis, the end-stage of declining kidney function, is closely linked with heart failure and diabetic nephropathy. Anti-inflammatory/anti-fibrotic mechanisms successfully navigated in MASH (e.g., combination DMTs with SGLT2 inhibitors) are being repurposed for CKD.
2. SSc (Systemic Sclerosis): A severe disease where fibrosis progresses not only in the skin but across multiple organs, including the lungs (SSc-ILD). Leading assets like LPA1 receptor antagonists aimed at IPF are advancing into late-stage clinical trials for SSc indication expansion.

For pipeline trends in CKD, please see our CKD and Renal Fibrosis Landscape.

Overcoming Disease Barriers: The Pan-Fibrosis Approach

Regardless of the organ afflicted, the fundamental mechanisms of fibrosis share many common traits. Shifting target profiles from being organ-dependent to mechanism-dependent—the "Pan-fibrosis" approach—is becoming mainstream.

• TGF-β Signaling Pathway: The "master regulator" of fibrosis. Many of the latest DMTs attempt to directly or indirectly inhibit this pathway.
• Extracellular Matrix (ECM) Regulation: An approach directly targeting the enzymes responsible for producing the final fibrotic products, such as collagen.
• Macrophage Polarization Control: An immune system-based strategy aiming to normalize tissue repair processes by managing the balance between M1/M2 macrophages.

Conclusion: Translational Research Support by SMC Laboratories

For anti-fibrotic drugs to achieve clinical success as DMTs (e.g., meeting surrogate marker endpoints), it is essential to select appropriate non-clinical models and evaluate highly accurate biomarkers geared toward human trials.

SMC Laboratories provides a comprehensive suite of multi-organ fibrosis models, beginning with our proprietary STAM™ mouse model for MASH and our bleomycin-induced model for IPF, alongside robust models for CKD and SSc. Coupled with our unique digital image analysis technology for fibrosis quantification, we powerfully support our clients' journeys toward indication expansion and securing early PoC for novel DMTs.

For inquiries and consultations, please contact us here.